US-based medical diagnostics company T2 Biosystems has raised $40m in its series E round including new investor, investment bank Goldman Sachs. 

The money will help develop T2Candida, the company’s molecular diagnostic test of species-specific Candida fungal infections directly from whole blood.

In 2001, T2 closed a $23m series D round of financing led by US-based investment firm Aisling Capital.

Also participating in the consortium was Physic Ventures, a corporate venturing fund backed by, among others, consumer goods conglomerate Unilever, food…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?